ABT-724

С Википедије, слободне енциклопедије
ABT-724
IUPAC ime
2-(4-piridin-2-ilpiperazin-1-ilmetil)-1H-benzimidazol
Identifikatori
CAS broj70006-24-5 ДаY
ATC kodnone
PubChemCID 5025739
ChemSpider4204515 ДаY
ChEMBLCHEMBL440687 ДаY
Hemijski podaci
FormulaC17H19N5
Molarna masa293,366 g/mol
  • n2c1ccccc1nc2CN(CC4)CCN4c3ncccc3
  • InChI=1S/C17H19N5/c1-2-6-15-14(5-1)19-16(20-15)13-21-9-11-22(12-10-21)17-7-3-4-8-18-17/h1-8H,9-13H2,(H,19,20) ДаY
  • Key:FRPJGTNLZNXQEX-UHFFFAOYSA-N ДаY

ABT-724 je lek koji deluje kao dopaminski agonist. On je selektivan za D4 podtip.[1] ABT-724 je razvijen kao mogući lek za impotenciju,[2] mada zbog slabe oralne biodostupnosti verovatno neće naći kliničku primenu.[3] On se koristi u naučnim istraživanjima funkcije D4 receptora.[4][5]

Reference[уреди | уреди извор]

  1. ^ Brioni JD, Moreland RB, Cowart M, Hsieh GC, Stewart AO, Hedlund P, Donnelly-Roberts DL, Nakane M, Lynch JJ, Kolasa T, Polakowski JS, Osinski MA, Marsh K, Andersson KE, Sullivan JP (2004). „Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats”. Proceedings of the National Academy of Sciences of the United States of America. 101 (17): 6758—63. PMC 404118Слободан приступ. PMID 15087502. doi:10.1073/pnas.0308292101. 
  2. ^ Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO (2004). „Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction”. Journal of Medicinal Chemistry. 47 (15): 3853—64. PMID 15239663. doi:10.1021/jm030505a. 
  3. ^ Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, Nelson SL, Cowart MD, Nakane M, Miller LN, Uchic ME, Terranova MA, El-Kouhen OF, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Chang R, Martino BR, Wetter JM, Marsh KC, Martin R, Darbyshire JF, Gintant G, Hsieh GC, Moreland RB, Sullivan JP, Brioni JD, Stewart AO (2006). „Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction”. Journal of Medicinal Chemistry. 49 (25): 7450—65. PMID 17149874. doi:10.1021/jm060662k. 
  4. ^ Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N, Cussac D (2008). „Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells”. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 11 (3): 293—307. PMID 17897483. doi:10.1017/S1461145707008061. 
  5. ^ Marona-Lewicka D, Chemel BR, Nichols DE (2009). „Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI”. Psychopharmacology. 203 (2): 265—77. PMID 18604600. doi:10.1007/s00213-008-1238-0. 

Vidi još[уреди | уреди извор]